Theralase Technologies Inc. V.TLT

U.S. funding 1.6B$ for Novavax's COVID-19

[ScienceFirst]

Examples of canadian-made Novavax vaccine that shines worldwide and that could happen to TLT, if it answers a specific unmet need:


U.S. funding to now cover study of Novavax's COVID-19 shot in adolescents

Feb 7, 2022 (Reuters) - Novavax Inc (NVAX.O) said on Monday U.S. government funding for its COVID-19 vaccine had been expanded to cover a late-stage study in adolescents with a booster component.

Novavax in July 2020 had received $1.6 billion in funding to develop its protein-based vaccine under a government program aimed at accelerating access to coronavirus vaccines and treatments, formerly called Operation Warp Speed.


Swissmedic grants conditional marketing authorization for Novavax COVID-19 vaccine for individuals aged 18 years or older in Switzerland.

Feb. 13, 2022 - Singapore grants interim approval for Novavax's COVID-19 ...

April 14, 2022 - Thai FDA grants EUA to Novavax-Serum Institute's Covid-19 ...

[CancerSlayer]

  At this point, I'm all for TLT continuing to pursue a comparable/better vaccine, but only as long as it continues to be fully government funded.  I'd rather see any limited company funds/private funding be targeted for ACT development & possibly advancing anti-viral treatment studies. Protein-based vaccines may be the next big game-changers for Covid-19 prevention imo.

[ScienceFirst]

Novavax is exclusively a vaccine company. It currently has a 4.2B$ market valuation for 222M$ in revenues (Dec. 2021). An oncology biotech with an approved drug is worth much more than a vaccine, just based on the fact that a late-stage cancer is usually more life-threatening than a virus. Novavax's current share price is 54$US. In Jan. 2020, it was 6$US.  July 2020, it touched 170$US.

[Pandora]

Is there a reason why you are referring to "Ph. 2B data"? i.e. why the B My understanding is that we are currently on a Phase 2 (II) Study? Are they synonymous? From the TLT website: Phase II NMIBC Clinical Study As the frontrunner in personalized Anti-Cancer Therapy (“ACT”) treatments for patients diagnosed with Non-Muscle Invasive Bladder Cancer

[Pandora]

Also, just a quick question from the previous post - the website says: "To date, 24 patients have been enrolled and treated in Study II." Based on our last update is the website out of date? Also it says "the Company has been advised by the FDA, to provide clinical assessment data for the primary, secondary and tertiary objective for approximately 20-25 patients treated at the

[ScienceFirst]

450-days of 20-25 patients is what the FDA probably requires, so it can better assess both CR% and DR%.  That's probably why TLT puts the BDt designation around Dec. 2022 and then commercial revenues Jan. 2023 whether from a jv upfront or via the Accelerated Approval program that allows you to get revenues from the drug while being in a clinical study.

[ScienceFirst]

4.2B$ valuation.  Down 60% in 6 months, 89% in 2y.  And we have 2 whiners recycled under new names in FPGstock and Gorf79 created within 1 day (April 4 and 5)!  Novavax Guides To At Least $4 Billion In 2022 Sales 04/18/2022 Novavax (NVAX) is working to expand use of its Covid vaccine, but NVAX stock remains under pressure in the second quarter. Doses are now